Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All paxlovid studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchPaxlovidPaxlovid (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   

African clinical trial denied access to key COVID drug Paxlovid

Ledford et al., Nature, doi:10.1038/d41586-022-00919-5
Apr 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
News reporting that Pfizer denied access to Paxlovid for an independent trial. The press release indicates that Pfizer has denied access for multiple groups1. Also see2.
Ledford et al., 4 Apr 2022, preprint, 2 authors.
This PaperPaxlovidAll
{ 'indexed': {'date-parts': [[2022, 4, 4]], 'date-time': '2022-04-04T18:42:17Z', 'timestamp': 1649097737983}, 'reference-count': 1, 'publisher': 'Springer Science and Business Media LLC', 'license': [ { 'start': { 'date-parts': [[2022, 4, 4]], 'date-time': '2022-04-04T00:00:00Z', 'timestamp': 1649030400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}, { 'start': { 'date-parts': [[2022, 4, 4]], 'date-time': '2022-04-04T00:00:00Z', 'timestamp': 1649030400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': ['Nature'], 'DOI': '10.1038/d41586-022-00919-5', 'type': 'journal-article', 'created': {'date-parts': [[2022, 4, 4]], 'date-time': '2022-04-04T18:03:38Z', 'timestamp': 1649095418000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': ['African clinical trial denied access to key COVID drug Paxlovid'], 'prefix': '10.1038', 'author': [ {'given': 'Heidi', 'family': 'Ledford', 'sequence': 'first', 'affiliation': []}, {'given': 'Amy', 'family': 'Maxmen', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2022, 4, 4]]}, 'reference': [ { 'key': 'CM20270880_CR1', 'doi-asserted-by': 'publisher', 'author': 'J. Hammon', 'year': '2022', 'unstructured': 'Hammon, J. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2118542 ' '(2022).', 'journal-title': 'N. Engl. J. Med.', 'DOI': '10.1056/NEJMoa2118542'}], 'container-title': ['Nature'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.nature.com/articles/d41586-022-00919-5.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/d41586-022-00919-5', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/d41586-022-00919-5.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 4, 4]], 'date-time': '2022-04-04T18:12:47Z', 'timestamp': 1649095967000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.nature.com/articles/d41586-022-00919-5'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 4, 4]]}, 'references-count': 1, 'alternative-id': ['CM20270880'], 'URL': 'http://dx.doi.org/10.1038/d41586-022-00919-5', 'relation': {}, 'ISSN': ['0028-0836', '1476-4687'], 'issn-type': [{'value': '0028-0836', 'type': 'print'}, {'value': '1476-4687', 'type': 'electronic'}], 'subject': ['Multidisciplinary'], 'published': {'date-parts': [[2022, 4, 4]]}}
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit